Although GLP-1 therapies have revolutionized obesity and diabetes management, important knowledge gaps remain in optimizing their long-term safety, tolerability, and body composition outcomes. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.